PT-141 (Bremelanotide)
PT-141 (Bremelanotide) is a hormone receptor activator that works directly in the brain, unlike blood flow-based medications for sexual dysfunction. It is FDA-approved as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
Verified sources for PT-141 (Bremelanotide)
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of PT-141 (Bremelanotide)
Activates melanocortin receptors in the central nervous system to enhance neural pathways involved in sexual desire and arousal.
Activates MC3R and MC4R receptors in the hypothalamus and limbic system, areas involved in sexual desire, arousal, and motivation.
Works directly on brain pathways to enhance sexual desire, a different mechanism from PDE-5 inhibitors that work peripherally on blood flow.
Influences dopaminergic and oxytocinergic pathways (proposed), affecting sexual response and pair bonding.
Produces dose-dependent erectile responses in men with organic erectile dysfunction, and is effective even in those unresponsive to PDE-5 inhibitors.
Increases desire and reduces distress associated with low sexual desire in premenopausal women with HSDD, an FDA-approved indication
Read Full PT-141 (Bremelanotide) Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Sexual Health & Libido